64 research outputs found

    Analysis of the conditional mutual information in ballistic and diffusive non-equilibrium steady-states

    Get PDF
    The conditional mutual information (CMI) I(A ⁣: ⁣C∣B)\mathcal{I}(A\! : \! C|B) quantifies the amount of correlations shared between AA and CC \emph{given} BB. It therefore functions as a more general quantifier of bipartite correlations in multipartite scenarios, playing an important role in the theory of quantum Markov chains. In this paper we carry out a detailed study on the behavior of the CMI in non-equilibrium steady-states (NESS) of a quantum chain placed between two baths at different temperatures. These results are used to shed light on the mechanisms behind ballistic and diffusive transport regimes and how they affect correlations between different parts of a chain. We carry our study for the specific case of a 1D bosonic chain subject to local Lindblad dissipators at the boundaries. In addition, the chain is also subject to self-consistent reservoirs at each site, which are used to tune the transport between ballistic and diffusive. As a result, we find that the CMI is independent of the chain size LL in the ballistic regime, but decays algebraically with LL in the diffusive case. Finally, we also show how this scaling can be used to discuss the notion of local thermalization in non-equilibrium steady-states

    NRAS Mutation Is the Sole Recurrent Somatic Mutation in Large Congenital Melanocytic Nevi

    Get PDF
    Congenital melanocytic nevus (CMN) is a particular melanocytic in utero proliferation characterized by an increased risk of melanoma transformation during infancy or adulthood. NRAS and BRAF mutations have consistently been reported in CMN samples, but until recently results have been contradictory. We therefore studied a series of large and giant CMNs and compared them with small and medium CMNs using Sanger sequencing, pyrosequencing, high-resolution melting analysis, and mutation enrichment by an enhanced version of ice-COLD-PCR. Large–giant CMNs displayed NRAS mutations in 94.7% of cases (18/19). At that point, the role of additional mutations in CMN pathogenesis had to be investigated. We therefore performed exome sequencing on five specimens of large–giant nevi. The results showed that NRAS mutation was the sole recurrent somatic event found in such melanocytic proliferations. The genetic profile of small–medium CMNs was significantly different, with 70% of cases bearing NRAS mutations and 30% showing BRAF mutations. These findings strongly suggest that NRAS mutations are sufficient to drive melanocytic benign proliferations in utero

    SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance

    Get PDF
    Renal medullary carcinoma (RMC) is an aggressive tumour driven by bi-allelic loss of SMARCB1 and tightly associated with sickle cell trait. However, the cell-of-origin and oncogenic mechanism remain poorly understood. Using single-cell sequencing of human RMC, we defined transformation of thick ascending limb (TAL) cells into an epithelial-mesenchymal gradient of RMC cells associated with loss of renal epithelial transcription factors TFCP2L1, HOXB9 and MITF and gain of MYC and NFE2L2-associated oncogenic and ferroptosis resistance programs. We describe the molecular basis for this transcriptional switch that is reversed by SMARCB1 re-expression repressing the oncogenic and ferroptosis resistance programs leading to ferroptotic cell death. Ferroptosis resistance links TAL cell survival with the high extracellular medullar iron concentrations associated with sickle cell trait, an environment propitious to the mutagenic events associated with RMC development. This unique environment may explain why RMC is the only SMARCB1-deficient tumour arising from epithelial cells, differentiating RMC from rhabdoid tumours arising from neural crest cells

    Deciphering the Epigenetic Changes Involved in Epithelial-Mesenchymal Transition and Cancer

    No full text
    La transition Ă©pithĂ©lio-MĂ©senchymateuse (TEM) est un processus de plasticitĂ© cellulaire qui existe dans le dĂ©veloppement embryonnaire et qui permet la formation des tissus et organes. Dans la cancĂ©rogĂ©nĂšse, ce processus est rĂ©activĂ© par des facteurs de transcription dont l’action implique trĂšs probablement un remodelage de la chromatine. La cartographie exacte de ces changements Ă©pigĂ©nĂ©tiques est peu connue Ă  l’échelle du gĂ©nome entier, mĂȘme si il y a eu quelques Ă©tudes antĂ©rieures explorant les changements de quelques loci de façon bien ciblĂ©e. Ce mĂ©moire traite du remodelage Ă©pigĂ©nĂ©tique mĂ©diĂ© par le facteur de transcription Twist1 dans un modĂšle de lignĂ©e mammaire immortalisĂ©e. L’architecture de ce remodelage a Ă©tĂ© cartographiĂ©e grĂące Ă  l’utilisation des techniques de haut-DĂ©bit pour analyser la mĂ©thylation de l’ADN (DREAM) et les modifications des histones (ChIPseq). Nos rĂ©sultats montrent un changement majeur du mĂ©thylome pendant la TEM avec une hypermĂ©thylation focale et une hypomĂ©thylation globale des corps des gĂšnes prĂ©dominant au niveau des « domaines partiellement mĂ©thylĂ©s »; ces domaines sont dĂ©jĂ  connus dans le dĂ©veloppement pour gagner de façon concomitante Ă  leur hypomĂ©thylation des marques d’histone rĂ©pressives. Nous avons aussi observĂ© un remodelage des domaines de l’histone rĂ©pressive H3K27me3 avec une rĂ©duction de leur taille, et surtout le quasi doublement du nombre de gĂšnes bivalents qui accompagne la transition. Le couplage de la mĂ©thylation de l’ADN avec le profil des microRNA nous a permis d’identifier le miR-203 comme l’unique microRNA rĂ©gulĂ© par mĂ©thylation de l’ADN durant la TEM; nous avons aussi montrĂ© que l’extinction Ă©pigĂ©nĂ©tique du miR-203 est requise pour la TEM et l’acquistion des propriĂ©tĂ©s de cellules souches. Enfin, nous avons rĂ©alisĂ© une caractĂ©risation gĂ©nĂ©tique et/ou Ă©pigĂ©nĂ©tique de deux cancers rares, les carcinomes fibrolamellaires du foie et les carcinomes du rein Ă  translocation. Pour les carcinomes fibrolamellaires du foie, nous avons dĂ©crit la nature endocrine de cette tumeur et Ă©tabli une signature Ă©pigĂ©nĂ©tique basĂ©e sur la mĂ©thylation de l’ADN pouvant servir Ă  diffĂ©rencier les formes histologiques appelĂ©es « pures » des formes « mixtes ». Pour les cancers du rein Ă  translocation, nous avons montrĂ© les bases gĂ©nĂ©tiques et Ă©pigĂ©nĂ©tiques de la diffĂ©rence entre les formes pĂ©diatriques et adultes, avec la dĂ©couverte frĂ©quente du gain du bras chromosomique 17q dans les formes adultes. Nous avons aussi identifiĂ© une mutation rĂ©currente dans le gĂšne qui remodĂšle la chromatine INO80D appartenant Ă  la famille INO80. En conclusion, ce travail explore le rĂŽle de l’étude de l’épigĂ©nome pour comprendre la reprogrammation pendant les processus physiologiques comme la TEM d’une part et le cancer d’autre part.The epithelial-Mesenchymal transition (EMT) is a process of cellular plasticity that exists in embryonic development and which allows the formation of tissues and organs. In carcinogenesis, the process is reactivated by transcription factors whose action probably involves chromatin remodeling. The exact mapping of these epigenetic changes is poorly understood genome-Wide, although there have been some previous studies exploring changes in so few well-Targeted loci. This thesis deals with the epigenetic remodeling mediated by the transcription factor Twist1 in a model of human mammary immortalized cell line. The architecture of this remodeling has been mapped through the use of high-Throughput techniques to analyze DNA methylation (DREAM) and histone modifications (ChIPseq). Our results suggest a major change in the EMT methylome with focal hypermethylation and gene body hypomethylation predominantly within "partially methylated domains"; these areas are already known in development to gain repressive histone marks concomitantly with DNA hypomethylation. We also observed landscape remodeling of repressive histone mark H3K27me3 with a reduction in domains size, and especially the almost doubling of the number of bivalent genes. The coupling of DNA methylation with the profile of microRNA has allowed us to identify miR-203 as single microRNA regulated by DNA methylation during EMT; we have also shown that epigenetic suppression of miR-203 is both required for EMT and acquisition of stem cell properties. Finally, we performed a genetic and/or epigenetic characterization of two rare cancers, named fibrolamellar hepatocellular carcinomas and translocation renal cell carcinomas. In fibrolamellar hepatocellular carcinoma, we described the endocrine nature of this tumor and established a signature based on DNA methylation which can be used to distinguish histological forms called "pure" from "mixed" fibrolamellar hepatocellular carcinomas. Regarding translocation renal cell carcinomas, we established the genetic and epigenetic basis of differences between pediatric and adult forms, characterized by frequent gain of 17q gain chromosomal arm in adults. We also identified recurrent mutations in the chromatin remodeling gene INO80D which belongs to INO80 family. In conclusion, this work explores the impact of analyzing the epigenome to understand reprogramming during physiological processes such as EMT and cancer

    Natural History and Treatment Strategies of Advanced PEComas: A Systematic Review

    No full text
    International audiencePEComas is a family of rare mesenchymal tumors. This systematic review aims to better understand the natural history of advanced PEComas. After a search on the PubMed database and main oncology meeting libraries according to the PRISMA guidelines, 88 articles reported in the English literature were included. Data on clinical and histological features, treatments and outcomes were collected. To identify risk factors, univariate and multivariate analyses were performed. Seven cohorts of patients and 124 individual patients were identified. Focusing on case reports, most patients were metastatic, and the median overall survival (OS) of the entire cohort was 60 months (95%CI 33; NA). Risk factors significantly associated with OS in the multivariate analysis were the presence of metastasis at diagnosis (HR: 2.59, 95%CI 1.06; 6.33, p = 0.036) and the grouped-Bleeker's risk category (HR: 4.66; 95%CI 1.07; 20.19; p = 0.039). In the metastatic population, only the presence of lymph node metastasis was associated with OS (HR: 3.11; 95%CI 1.13; 8.60, p < 0.05). Due to a lack of events, it was not possible to conclude on other factors. This review of the literature highlights the heterogeneity of literature data and shows the great diversity of clinical management strategies

    Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities

    No full text
    Sarcomatoid features in renal cell carcinoma (RCC) have long been associated with dismal prognosis and poor response to therapy, while biological mechanisms underpinning sarcomatoid dedifferentiation remained obscure. Several efforts have been conducted to break down the molecular profile of sarcomatoid RCC and investigate different targeted therapeutic approaches. Mutations enriched for in sarcomatoid RCC involve, notably, TP53, BAP1, cell cycle, and chromatin-remodeling genes. The immunological landscape of these tumors is also gradually being uncovered, showing frequent expression of programmed cell death ligand-1 (PD-L1) and high levels of tumor-infiltrating lymphocytes. These features may be major determinants for the activity of immune checkpoint inhibitors in this population, which has been confirmed by retrospective studies and subgroup analyses of large randomized phase 3 trials. Combinations based on PD-1/PD-L1 inhibition have demonstrated response rates and complete responses in &gt;50% and &gt;10% of patients in the first-line metastatic setting, respectively, with median overall survival exceeding two years. This remarkable improvement in outcomes effectively establishes immune checkpoint inhibitor combinations as a new standard of care in patients with sarcomatoid RCC. New research fields, including epigenetic regulations and tumor&ndash;microenvironment interactions, may further sharpen understanding of sarcomatoid RCC and advance therapeutic developments

    Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions

    No full text
    Upper tract urothelial carcinoma (UTUC) represents a rare and aggressive malignancy arising from the renal pelvis or ureter. It can develop sporadically or have a hereditary origin, such as Lynch syndrome, caused by DNA mismatch repair deficiency, leading to microsatellite instability phenotype. According to molecular characterization studies, UTUC presents different mutational profiles as compared to urinary bladder urothelial carcinomas. In particular, it has been reported that UTUC harbored a higher level of FGFR3 alterations associated with a T-cell depleted immune microenvironment. The therapeutic landscape in urothelial carcinoma is rapidly evolving, with immune checkpoint inhibitors forming part of the standard of care. A greater understanding of the molecular alterations and immune microenvironment leads to the development of new treatment combinations and targeted therapy. This review summarizes the available evidence concerning the use of immune checkpoint inhibitors and the biological rationale underlying their use in high-grade UTUC

    Molecular analysis for refractory rare cancers: Sequencing battle continues – learnings for the MOSCATO-01 study

    No full text
    International audienceBackground: For patients with metastatic rare cancers, treatments are limited. How systematic tumor sequencing can improve therapeutic possibilities in this population? Patients and methods: Patients with rare cancer were identified in the MOSCATO-01 trial. Patients’ outcome was measured by progression-free survival (PFS) and overall survival (OS). Results: The most frequently identified histologic subypes were ovarian adenocarcinoma (N = 13), carcinoma of unknown primary (N = 11), and leiomyosarcoma (N = 10). Ninety-nine (39%) of them had at least one targetable cancer molecular alteration Forty-nine patients (50%) received the therapy proposed by the molecular tumor board, and 13 patients (26%, 95%CI 15–41%) achieved a PFS2/PFS1 > 1.3. The median PFS2 on matched treatment subgroup was 2.3 months (95% CI 1.8–3.6) and the median OS was 11.4 months (95% CI 9–15.5). Conclusions: The molecular screening of patients with refractory, metastatic rare cancers might increase the therapeutic options. Facilitating access strategy to molecular-driven clinical trials or agnostic-approved treatment is crucial
    • 

    corecore